Loading...

FITC anti-mouse I-A/I-E Antibody

Pricing & Availability
Clone
M5/114.15.2 (See other available formats)
Regulatory Status
RUO
Other Names
MHC class II
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
m5/114.15.2 FITC
C57BL/6 mouse splenocytes were stained with anti-mouse I-A/I-E (clone M5/114.15.2) FITC (solid line) or rat IgG2b, κ FITC isotype control (dashed line).
  • m5/114.15.2 FITC
    C57BL/6 mouse splenocytes were stained with anti-mouse I-A/I-E (clone M5/114.15.2) FITC (solid line) or rat IgG2b, κ FITC isotype control (dashed line).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
107605 50 µg 57€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
107606 500 µg 176€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

These class II molecules are expressed on antigen presenting cells (including B cells) and a subset of T cells from H-2b,d,q,r bearing mice and are involved in antigen presentation to T cells expressing CD3/TCR and CD4 proteins.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Activated C57BL/6 mouse spleen cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The M5/114.15.2 antibody reacts with a polymorphic determinant shared by the I-Ab, I-Ad, I-Aq, I-Ed, and I-Ek MHC class II alloantigens from mice carrying H-2p,r,q,b,d,u haplotypes. Clone M5/114.15.2 however does not react wtih I-Af, I-Ak, or I-As MHC class II alloantigens.1

Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemistry of frozen sections2,3,6, in vitro and in vivo blocking of antigen presentation or ligand binding4-7, and spatial biology (IBEX)17,18. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 107655 & 107656).

Application References

(PubMed link indicates BioLegend citation)
  1. Bhattacharya A, et al. 1981. J. Immunol. 127:2488. (IP)
  2. Viville S, et al. 1993. Cell 72:635. (IHC)
  3. Nelson AJ, et al. 1993. J. Immunol. 151:2453. (IHC)
  4. Shi Y, et al. 1998. J. Exp. Med. 187:367. (Block)
  5. Yamashita I, et al. 1993. Int. Immunol. 5:1139.
  6. Guo M, et al. 1995. Zygote 3:65. (IHC)
  7. Kim A, et al. 2004. Exp. Mol. Med. 36:428. (Block)
  8. Luckashenak NA, et al. 2006. J. Immunol. 177:5177.
  9. Venanzi ES, et al. 2007. J. Immunol. 179:5693.
  10. Christensen SR, et al. 2006. Immunity 25:417. PubMed
  11. Matte-Martone C, et al. 2008. Blood 111:3884. PubMed
  12. De Pascalis R, et al. 2008. Infect. Immun. 76:4311. PubMed
  13. Kuns RD, et al. 2009. Blood 113:5999. PubMed
  14. Sabatino JJ, et al. 2011. J. Exp. Med. 208:81. PubMed
  15. Draber P, et al. 2011. Mol Cell Biol. 22:4550. PubMed
  16. Fu H, et al. 2014. Nat Commun. 5:3436. PubMed
  17. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  18. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Koyama M, et al. 2015. J Exp Med. 212: 1303 - 1321. PubMed
  2. Nguyen T, et al. 2021. STAR Protoc. 2:101004. PubMed
  3. Wang S, et al. 2022. Sci Adv. 8:eabn3883. PubMed
  4. Gargaro M, et al. 2022. Immunity. 55:1032. PubMed
  5. Mugarza E, et al. 2022. Sci Adv. 8:eabm8780. PubMed
  6. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  7. Montilla A, et al. 2023. Cell Death Dis. 14:16. PubMed
  8. Tanaka T, et al. 2023. Nat Immunol. 24:439. PubMed
  9. Drummer C, et al. 2023. Front Immunol. 14:1113883. PubMed
  10. Yang Z, et al. 2022. J Nucl Med. 63:1708. PubMed
  11. Lopez R, et al. 2022. Nat Biotechnol. 40:1360. PubMed
  12. Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed
  13. Sheng YH, et al. 2022. Cell Mol Gastroenterol Hepatol. 14:789. PubMed
  14. Qiu Z, et al. 2022. J Exp Med. 219:. PubMed
  15. Sauter M, et al. 2022. STAR Protoc. 3:101664. PubMed
  16. Pagni RL, et al. 2022. Front Immunol. 13:1005937. PubMed
  17. Chen X, et al. 2023. Adv Mater. 35:e2210440. PubMed
  18. Zhao Q, et al. 2023. Signal Transduct Target Ther. 8:40. PubMed
  19. Do-Thi VA, et al. 2023. Cancer Res Commun. 3:80. PubMed
  20. Guo Z, et al. 2023. Int J Mol Sci. 24:. PubMed
  21. Yao H, et al. 2023. Front Immunol. 14:1147674. PubMed
  22. Shen Z, et al. 2023. iScience. 26:106572. PubMed
  23. He Y, et al. 2023. Biomolecules. 13:. PubMed
  24. Hsieh MS, et al. 2023. NPJ Vaccines. 8:82. PubMed
  25. Yao RQ, et al. 2023. Mil Med Res. 10:27. PubMed
  26. Du J, et al. 2020. Developmental Cell. 55(6):737-753.e7. PubMed
  27. Orillion A, et al. 2018. Clin Cancer Res. 24:6383. PubMed
  28. Mulder R, et al. 2017. Front Immunol. 1.464583333. PubMed
  29. Sim SL, et al. 2022. Front Endocrinol (Lausanne). 13:957833. PubMed
  30. Tarban N, et al. 2022. Cells. 11:. PubMed
  31. Jong RM, et al. 2022. J Immunol. 208:407. PubMed
  32. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  33. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  34. Pierini S, et al. 2021. J Immunother Cancer. 9:. PubMed
  35. Nakamura M, et al. 2015. J Immunol. 194:243. PubMed
  36. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  37. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  38. Hickey A, et al. 2021. Front Microbiol. 12:653587. PubMed
  39. Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed
  40. Sauter M, et al. 2022. iScience. 25:103677. PubMed
  41. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  42. Dutta S, et al. 2012. Eukaryot Cell. 0.756944444. PubMed
  43. He Y, et al. 2020. Sci Adv. 6:eaba7589. PubMed
  44. Hays C, et al. 2020. eLife. 8:e48772.. PubMed
  45. Sultan H, et al. 2018. Cancer Immunol Res. 6:617. PubMed
  46. Zhao J, et al. 2019. Nat Commun. 10:899. PubMed
  47. Matsumura F, et al. 2021. J Immunol. 207:938. PubMed
  48. Zhu B, et al. 2021. Immunity. 54(6):1200-1218.e9. PubMed
  49. Enriquez AB, et al. 2022. iScience. 25:104305. PubMed
  50. Renga G, et al. 2020. Life Sci Alliance. 3:. PubMed
  51. Ayasoufi K, et al. 2020. Brain. 3629:143. PubMed
  52. Wang H et al. 2017. Developmental cell. 40(6):566-582 . PubMed
  53. Kimura A, et al. 2018. J Exp Med. 215:2197. PubMed
  54. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  55. Qu J, et al. 2018. J Immunol Res. 2018:7519856. PubMed
  56. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  57. Wang L, et al. 2021. Cancer Immunol Res. 9:348. PubMed
  58. Enriquez AB, et al. 2022. iScience. 25:104305. PubMed
  59. Mainz RE, et al. 2022. Cells. 11:. PubMed
  60. Zhao F, et al. 2022. Front Immunol. 13:873720. PubMed
  61. Carozza JA, et al. 2020. Nat Cancer. 184:1. PubMed
  62. Wang Y, et al. 2021. Sci Rep. 1.429861111. PubMed
  63. Reynolds A, et al. 2015. J Immunol. 194:231. PubMed
  64. Morris E, et al. 2005. J Clin Invest. 115:3093. PubMed
  65. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  66. Tsukasaki M, et al. 2020. Cell Reports. 32(10):108124. PubMed
  67. Hernández–Santos N, et al. 2018. Cell Host Microbe. 1.313194444. PubMed
  68. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
  69. Kang SJ, et al. 2022. Food Sci Anim Resour. 42:903. PubMed
  70. Miki Y, et al. 2016. J Biol Chem. 291: 15588 - 15601. PubMed
  71. Kaplan D, et al. 2007. J Exp Med. 204:2545. PubMed
  72. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  73. Zou J, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:983. PubMed
  74. Dobosz E, et al. 2021. Dis Model Mech. :14. PubMed
  75. Bayik D, et al. 2020. Cancer Discov. 1.256944444. PubMed
  76. Koma T, et al. 2014. J Virol. 88:7178. PubMed
  77. Pradhan K, et al. 2021. Front Immunol. 12:778830. PubMed
  78. White C, et al. 2015. J Immunol. 194:697. PubMed
  79. Engler AE, et al. 2020. Cell Reports. 33(13):108553. PubMed
  80. Kim SH, et al. 2021. Cell Reports. 35(2):108995. PubMed
  81. Donaldson B, et al. 2017. J Immunother Cancer. 10.1186/s40425-017-0270-1. PubMed
  82. Zhang J, et al. 2018. Sci Rep. 8:2373. PubMed
  83. Hakim R, et al. 2019. Stem Cell Res Ther. 10:115. PubMed
  84. Kramer K, et al. 2017. ACS Omega. 0.240972222. PubMed
  85. Vorselen D, et al. 2021. Elife. 10:. PubMed
  86. Koikawa K, et al. 2021. Cell. 184:4753. PubMed
  87. Dewi IMW, et al. 2021. Cell Reports Medicine. 2(5):100289. PubMed
  88. Maisel D, et al. 2016. PLoS One. 11: 0159716. PubMed
  89. Steinbach K, et al. 2013. J Immunol. 191:4531. PubMed
  90. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  91. Otvos B, et al. 2021. Clin Cancer Res. 27:2038. PubMed
  92. Maulloo CD, et al. 2021. Front Immunol. 12:714842. PubMed
  93. Van Dis E, et al. 2018. Cell Rep. 23:1435. PubMed
  94. Guo S, et al. 2021. Sci Rep. 11:23745. PubMed
  95. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  96. Zhao L, et al. 2021. STAR Protocols. 2:100732. PubMed
  97. Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed
  98. Banovic T, et al. 2009. J Immunol. 182:912. PubMed
  99. Zwick M, et al. 2019. Front Immunol. 10:222. PubMed
  100. Ghorbani S, et al. 2022. Nat Commun. 13:2445. PubMed
  101. Hidaka T, et al. 2016. Nat Immunol. 18:64-73. PubMed
  102. Budai Z, et al. 2021. Cells. 10:. PubMed
  103. Luo M, et al. 2021. J Immunol. 207:1683. PubMed
  104. Bagati A, et al. 2020. Cancer Cell. 39(1):54-67.e9. PubMed
  105. Moufarrij S, et al. 2020. Sci Rep. 10:3470. PubMed
  106. Wu J, et al. 2019. J Immunol Res. 2019:1749803. PubMed
  107. Kelly SH, et al. 2021. Adv Healthc Mater. 10:e2001614. PubMed
  108. Schulz A, et al. 2015. J Biol Chem. 211: 553 - 567. PubMed
  109. Kramer K, et al. 2017. Mol Ther. 25(1):62-70. PubMed
  110. Wijayadikusumah A, et al. 2017. Amino Acids. 10.1007/s00726-017-2466-6. PubMed
  111. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  112. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  113. Xiao S, Manley N 2010. PLoS One. 5:e15396. PubMed
  114. Grube J, et al. 2022. Cell Death Dis. 13:704. PubMed
  115. Aguilera TA, et al. 2020. Clin Cancer Res. 26:2972. PubMed
  116. Danne C et al. 2017. Cell host & microbe. 22(6):733-745 . PubMed
  117. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  118. Xiao Z, et al. 2022. Mater Today Bio. 15:100297. PubMed
  119. Nicholls J, et al. 2021. Front Cell Dev Biol. 9:737880. PubMed
  120. Chetty A, et al. 2021. Cell Host Microbe. 29:579. PubMed
  121. Stack G, et al. 2015. PLoS Pathog. 11:1004641. PubMed
  122. Harberts E, et al. 2015. J Immunol. 194:3127. PubMed
  123. Tran S, et al. 2020. Immunity. 53(3):627-640.e5. PubMed
  124. Arima Y et al. 2017. eLife. 6 pii: e25517. PubMed
  125. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  126. Krotova K, et al. 2019. Mol Ther Oncolytics. 15:166. PubMed
  127. Steinmann S, et al. 2020. Sci Rep. 1.160416667. PubMed
  128. Al-Zaeed N, et al. 2021. Cell Death Dis. 12:611. PubMed
  129. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  130. Spanier J, et al. 2016. Nat Commun. 7:11804. PubMed
  131. Dong S, et al. 2007. Int Immunopharmacol. 7:725. PubMed
  132. Park CJ, et al. 2020. Cell Reports. 31(2):107496.. PubMed
  133. Deets KA, et al. 2021. Elife. 10:. PubMed
RRID
AB_313320 (BioLegend Cat. No. 107605)
AB_313320 (BioLegend Cat. No. 107606)

Antigen Details

Structure
MHC class II
Distribution

B cell and activated T cells, APCs of the H-2b,d,q,r bearing mice

Function
Antigen presentation
Ligand/Receptor
CD3/TCR, CD4
Cell Type
Antigen-presenting cells, B cells, Dendritic cells, T cells, Tregs
Biology Area
Immunology, Innate Immunity
Molecular Family
MHC Antigens
Antigen References

1. Watts C. 1997. Ann. Rev. Immunol. 15:821.
2. Pamer E, et al. 1998. Ann. Rev. Immunol. 16:323.

Gene ID
14961 View all products for this Gene ID 14969 View all products for this Gene ID
UniProt
View information about I-A/I-E on UniProt.org

Other Formats

View All I-A/I-E Reagents Request Custom Conjugation
Description Clone Applications
Biotin anti-mouse I-A/I-E M5/114.15.2 FC
FITC anti-mouse I-A/I-E M5/114.15.2 FC
PE anti-mouse I-A/I-E M5/114.15.2 FC
Purified anti-mouse I-A/I-E M5/114.15.2 FC,IHC-F,IP,Block
PE/Cyanine5 anti-mouse I-A/I-E M5/114.15.2 FC
APC anti-mouse I-A/I-E M5/114.15.2 FC
Alexa Fluor® 488 anti-mouse I-A/I-E M5/114.15.2 FC,3D IHC
Alexa Fluor® 647 anti-mouse I-A/I-E M5/114.15.2 FC
Pacific Blue™ anti-mouse I-A/I-E M5/114.15.2 FC
Alexa Fluor® 700 anti-mouse I-A/I-E M5/114.15.2 FC,SB
PerCP/Cyanine5.5 anti-mouse I-A/I-E M5/114.15.2 FC
PerCP anti-mouse I-A/I-E M5/114.15.2 FC
APC/Cyanine7 anti-mouse I-A/I-E M5/114.15.2 FC
PE/Cyanine7 anti-mouse I-A/I-E M5/114.15.2 FC
Brilliant Violet 421™ anti-mouse I-A/I-E M5/114.15.2 FC,IHC-F,SB
Brilliant Violet 510™ anti-mouse I-A/I-E M5/114.15.2 FC
Purified anti-mouse I-A/I-E (Maxpar® Ready) M5/114.15.2 FC,CyTOF®
Brilliant Violet 605™ anti-mouse I-A/I-E M5/114.15.2 FC
Brilliant Violet 650™ anti-mouse I-A/I-E M5/114.15.2 FC
Brilliant Violet 711™ anti-mouse I-A/I-E M5/114.15.2 FC
Brilliant Violet 785™ anti-mouse I-A/I-E M5/114.15.2 FC
PE/Dazzle™ 594 anti-mouse I-A/I-E M5/114.15.2 FC
Alexa Fluor® 594 anti-mouse I-A/I-E M5/114.15.2 IHC-F,3D IHC
APC/Fire™ 750 anti-mouse I-A/I-E M5/114.15.2 FC
TotalSeq™-A0117 anti-mouse I-A/I-E M5/114.15.2 PG
Ultra-LEAF™ Purified anti-mouse I-A/I-E M5/114.15.2 FC,IHC-F,IP,Block
TotalSeq™-B0117 anti-mouse I-A/I-E M5/114.15.2 PG
TotalSeq™-C0117 anti-mouse I-A/I-E M5/114.15.2 PG
Spark Blue™ 550 anti-mouse I-A/I-E M5/114.15.2 FC
PE/Fire™ 640 anti-mouse I-A/I-E M5/114.15.2 FC
Spark YG™ 581 anti-mouse I-A/I-E M5/114.15.2 FC
PE/Fire™ 810 anti-mouse I-A/I-E M5/114.15.2 FC
Spark UV™ 387 anti-mouse I-A/I-E M5/114.15.2 FC
Spark Violet™ 538 anti-mouse I-A/I-E M5/114.15.2 FC
PerCP/Fire™ 806 anti-mouse I-A/I-E M5/114.15.2 FC
Spark Red™ 718 anti-mouse I-A/I-E M5/114.15.2 FC
APC/Fire™ 810 anti-mouse I-A/I-E M5/114.15.2 FC
Spark PLUS UV395™ anti-mouse I-A/I-E M5/114.15.2 FC
Go To Top Version: 4    Revision Date: 10.30.2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account